“`html
Human Herpes Virus-6 (HHV-6) Reactivation after Hematopoietic Cell Transplant and Chimeric Antigen Receptor (CAR)- T Cell Therapy: A Shifting Landscape
Key Points:
- HHV-6B reactivation affects about half of HCT recipients and can lead to various complications.
- ciHHV6, a persistent form of HHV-6, can complicate diagnosis and is associated with adverse outcomes.
- Recent changes in clinical practice require updated studies on the role of HHV-6B in current cellular therapies.
- No established treatment for HHV-6B exists, and preventive strategies face challenges due to high antiviral toxicity.
HHV-6B reactivation is a common issue after HCT and CAR-T cell therapy, leading to various complications. The persistent form of HHV-6, known as ciHHV6, can complicate diagnosis and is linked to adverse outcomes. Recent changes in clinical practice, such as the use of post-HCT cyclophosphamide and novel cellular therapies, require updated studies to understand the impact of HHV-6B in the current era. Currently, there is no established treatment for HHV-6B, and preventive strategies face challenges due to high antiviral toxicity. Ongoing research is crucial to keep up with the evolving epidemiology and impact of HHV-6 in diverse and expanding immunocompromised patient populations.
“`
